| Publications | PubMed=6864164; DOI=10.1084/jem.158.1.53
Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J.
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983) PubMed=1716514
Albino A.P., Davis B.M., Nanus D.M.
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.
Cancer Res. 51:4815-4820(1991) PubMed=7747814
Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H., Cordon-Cardo C., Kamb A.
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Am. J. Pathol. 146:1199-1206(1995) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311
Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M., Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T., Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L., Sharpless N.E.
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Cancer Res. 67:1502-1512(2007) PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958
Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011) PubMed=21725359; DOI=10.1038/onc.2011.250
Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B.
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625
Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) PubMed=25502142; DOI=10.1038/ncomms6712
Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C., Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H., Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G., Graeber T.G., Ribas A., Lo R.S., Peeper D.S.
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Nat. Commun. 5:5712.1-5712.15(2014) PubMed=25728708; DOI=10.1111/pcmr.12364
Vogel C.J., Smit M.A., Maddalo G., Possik P.A., Sparidans R.W., van der Burg S.H., Verdegaal E.M.E., Heck A.J.R., Samatar A.A., Beijnen J.H., Altelaar A.F.M., Peeper D.S.
Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Pigment Cell Melanoma Res. 28:307-317(2015) |
|---|